Email this article Experience with one-stage operations for bilateral nephroblastoma
- Authors: Kazantsev A.P.1,2, Rubansky M.A.1,2, Rubanskaya M.V.1,2, Kerimov P.A.1,2, Kapkova O.A.1,2, Rybakova D.V.1,2, Boichenko E.I.1,2, Khizhnikov A.V.1,2
-
Affiliations:
- Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Institute
- 23, Kashirskoe Shosse, Moscow 115 478, Russia
- Issue: Vol 11, No 1 (2015)
- Pages: 26-29
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER
- Published: 30.03.2015
- URL: https://oncourology.abvpress.ru/oncur/article/view/414
- DOI: https://doi.org/10.17650/1726-9776-2015-1-26-29
- ID: 414
Cite item
Full Text
Abstract
The paper describes the personal experience with one-stage operations for bilateral nephroblastoma (BN) in children.
In 2000 to 2012, the Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Institute, performed one-stage surgical interventions in 21 (26.2 %) children with BN. Their age ranged from 10 months to 5 years. The one-stage surgery as bilateral nephrectomy was made in 9 children. Nephrectomy with one-stage resection of the contralateral kidney was carried out in 4 children; 4 patients underwent one-stage surgery as resection of one kidney and biopsy of the other and 4 patients had nephrectomy and biopsy of the second kidney.
BN is a rare disease as suggested by the data available in the world literature; each new report on patients with BN is of great scientific and practical interest. The rate of BN is 4 to 10 % of all kidney cancers in children. Synchronous and metachronous kidney injuries are encountered in 5–7 and 2–3 % of cases, respectively. Bilateral renal involvement is more commonly diagnosed in younger children. The major peak incidence of BN occurs from ages 3 to 5 years. The disease is rarely diagnosed in children above 10 years. Boys and girls are equally frequently ill.
About the authors
A. P. Kazantsev
Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Institute; 23, Kashirskoe Shosse, Moscow 115 478, Russia
Author for correspondence.
Email: oncoanat@mail.ru
Russian Federation
M. A. Rubansky
Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Institute; 23, Kashirskoe Shosse, Moscow 115 478, RussiaRussian Federation
M. V. Rubanskaya
Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Institute; 23, Kashirskoe Shosse, Moscow 115 478, RussiaRussian Federation
P. A. Kerimov
Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Institute; 23, Kashirskoe Shosse, Moscow 115 478, RussiaRussian Federation
O. A. Kapkova
Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Institute; 23, Kashirskoe Shosse, Moscow 115 478, RussiaRussian Federation
D. V. Rybakova
Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Institute; 23, Kashirskoe Shosse, Moscow 115 478, RussiaRussian Federation
E. I. Boichenko
Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Institute; 23, Kashirskoe Shosse, Moscow 115 478, RussiaRussian Federation
A. V. Khizhnikov
Research Institute of Pediatric Oncology and Hematology, N.N. Blokhin Russian Cancer Research Institute; 23, Kashirskoe Shosse, Moscow 115 478, RussiaRussian Federation
References
Supplementary files
